COVID-19: investing in country capacity to bridge science, policy and action

Tanja Kuchenmüller, John C Reeder, Ludovic Reveiz, Goran Tomson, Fadi El-Jardali, John N Lavis, Arash Rashidian, Marge Reinap, John T Grove, Soumya Swaminathan

The COVID-19 pandemic has put research evidence and its use in health policy-making under a new spotlight. Faced with the need for immediate action, as most recently shown with vaccination roll-out strategies, many politicians and other leaders have publicly stressed the need to follow the ‘science’. Scientific advisors and advisory bodies have gained unprecedented visibility. At the same time, the conflicts between researchers/health experts and political decision-makers have, now and then, been vividly brought to the fore. To bridge the divide, building and strengthening knowledge translation (WHO defines knowledge translation as the exchange, synthesis and effective communication of reliable and relevant research results. The focus is on promoting interaction among the producers and users of research, removing the barriers to research use, and tailoring information to different target audiences so that effective interventions are used more widely.) organisations, which act as institutional bridges between researchers and both decision-makers and communities, is called for. More than ever before, countries need to counter misinformation and rapidly mobilise the best available evidence, and present it in user-friendly ways to decision-makers.

The WHO has been championing the need for research evidence to inform decision-making in the context of COVID-19. Although at times also challenged to provide clear guidance in the face of uncertainties (as the case of wearing face masks exemplified), the Organisation is uniquely positioned to function as a global knowledge broker. Using its convening power, early on WHO brought together leading experts to develop a global COVID-19 research roadmap to coordinate international research efforts. Examples include generation of new knowledge through the multicountry Solidarity Trial of candidate treatments for COVID-19, and cohosting the Access to COVID-19 Tools Accelerator for the development of and access to vaccines and diagnostics. WHO has also played a key role in developing rapid evidence syntheses and up-to-date technical guidance on COVID-19 to respond to Member States’ needs. Further support is, however, required to strengthen country capacity in adapting these syntheses to specific contexts and enhancing uptake and implementation at the local level.

While WHO has long promoted knowledge translation, it has stepped up its support to countries by establishing its Science Division and scaling up the Evidence-informed Policy Network (EVIPNet), a global knowledge translation network that aims to promote and institutionalise country capacity for evidence-informed decision-making and action. Throughout the pandemic, EVIPNet members have often been reference institutions for synthesising and contextualising the best available evidence to address country questions, and disseminating actionable evidence to target groups. They have also been key founding partners in COVID-19 Evidence Network to support Decision-making—has strength end of article.
The COVID-19 pandemic has demonstrated that the challenges of evidence-informed policy-making are not confined to low-resource settings; even countries with long traditions in knowledge translation have been tested to the extreme.14 To increase country resilience, much needs to be done. Investments are needed to strengthen the knowledge translation capacity of researchers, policymakers and other stakeholders. Well-grounded partnerships are critical in times of crisis and uncertainty. A deeper understanding of each other’s needs allows for the creation of trust and credibility, which form the basis for action in challenging times. Brokerage organisations are urged to rely on systematic and transparent procedures to avoid conflicts of interest that may jeopardise their status as credible, independent sources of evidence, and expand regular foresight and rapid response activities in response to changing needs and contexts. To mitigate inherent, uneven power relations, the evidence ecosystem (defined as ‘a system reflecting the formal and informal linkages and interactions between different actors [and their capacities and resources] involved in the production, translation and use of evidence’15) in a post-COVID-19 world would also need to become more demand-driven and oriented towards the evidence that is needed in policy and action, not just immediately, but in the months and years ahead, which requires a shift in the existing ‘incentive’ system of researchers (publish or perish). Finally, the actors of evidence ecosystems as a whole—evidence producers and users—are called on to create strong multisectoral and multidisciplinary collaborations and coordinate their efforts to reduce research waste, promote synergy and establish open, transparent and integrated systems.16

With EVIPNet and its partners, WHO is working towards building Member States’ capacity in equity-centred evidence-informed decision-making, including the strengthening of knowledge brokering organisations, developing standardised knowledge translation approaches and promoting stronger dialogue and collaboration between communities of the evidence ecosystem. Further technical and funding partners are being sought to make a meaningful difference to health and development in countries working towards strengthening country resilience and achieving the 2030 Agenda for Sustainable Development.

Author affiliations
1Department of Research for Health, World Health Organization, Geneva, Switzerland
2Department of Evidence and Intelligence for Action in Health and Incident Management System for COVID-19, WHO Regional Office for the Americas/Pan American Health Organization, Washington, District of Columbia, USA
3President’s Office, Karolinska Institutet, Stockholm, Stockholm, Sweden
4Swedish Institute for Global Health Transformation, Royal Swedish Academy of Sciences, Stockholm, Sweden
5Knowledge to Policy (K2) Center/WHO Collaborating Centre for Evidence-Informed Policymaking and Practice, American University of Beirut, Beirut, Lebanon
6Department of Health Management and Policy, American University of Beirut, Beirut, Lebanon
7McMaster Health Forum/WHO Collaborating Centre for Evidence-Informed Policy, McMaster University, Hamilton, Ontario, Canada
8Department of Health Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
9Department of Science, Information and Dissemination, World Health Organisation Regional Office for the Eastern Mediterranean, Cairo, Egypt
10Division of Country Health Policies and System, World Health Organization Regional Office for Europe, Copenhagen, Denmark
11Department of Quality Assurance, Norms and Standards, World Health Organization, Geneva, Switzerland
12Office of Chief Scientist, World Health Organization, Geneva, Switzerland

Acknowledgements The authors would like to thank Bandana Mahotra for her editorial support.

Contributors TK and JCR conceptualised the comment. TK wrote the comment in close consultation with and input from JCR, LR and GT. All coauthors provided substantial contributions in terms of design and critical revision of the draft, and reviewed as well as approved the final version to be submitted for publication. The comment was developed under the leadership and oversight of SS.

Funding Funding of the WHO was used for the editing of the comment.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement There are no data in this work.

Open access This is an open access article distributed in the terms of the Creative Commons Attribution-Non commercial 4.0 International License (CC BY-NC 4.0), which permits use, distribution, and reproduction for non-commercial purposes in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.

ORCID iD Tanja Kuchenmüller http://orcid.org/0000-0002-9021-981X

REFERENCES


